Hospital
Sutter Valley Hospitals
Sutter Valley Hospitals was paid $26.09M by Medicaid between Jan 2018 and Nov 2024, across 238 billing codes. Its largest line is 99281, Emergency department visit for the evaluation and management, self-limited or minor — 25% of everything it billed.
33Billing provider infoSUTTER VALLEY HOSPITALS
LOS BANOS, CA 93635
LOS BANOS, CA 93635
33aNPI1366896300assigned 04/15/2016
33bProvider typeGeneral Acute Care Hospital
28Total paid$26.09M
24GClaims813,471
24DCodes billed238
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#102 of 410
Median peer was paid$6.90M
This provider vs. median3.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 119,243 | $2.52M | |
| 2019 | 120,840 | $3.27M | |
| 2020 | 87,220 | $2.96M | |
| 2021 | 103,605 | $3.51M | |
| 2022 | 121,612 | $4.62M | |
| 2023 | 132,262 | $4.61M | |
| 2024incomplete | 128,689 | $4.61M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 25% | 98,218 | 87,032 | $6.41M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.6% | 6,142 | 5,963 | $1.45M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.9% | 16,928 | 15,363 | $1.28M |
| 70450 | Computed tomography, head or brain; without contrast material | 4.2% | 6,126 | 5,980 | $1.11M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 3.3% | 4,123 | 4,038 | $867K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 3.1% | 4,015 | 3,930 | $820K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.5% | 12,629 | 11,035 | $661K |
| 80053 | Comprehensive metabolic panel | 2.3% | 52,410 | 46,957 | $598K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.2% | 17,335 | 16,045 | $579K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.0% | 61,927 | 54,973 | $517K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.9% | 5,492 | 4,866 | $487K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.7% | 6,790 | 6,564 | $452K |
226 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.6% | 5,552 | $415K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.5% | 1,739 | $392K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.5% | 3,541 | $388K |
| 99213 | Doctor's office visit, returning patient (routine) | 1.5% | 3,374 | $381K |
| 0450 | Emergency room services | 1.3% | 8,118 | $329K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.2% | 1,428 | $308K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 12,444 | $279K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.1% | 3,383 | $275K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.0% | 7,056 | $270K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.0% | 5,578 | $263K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,080 | $237K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 11,552 | $236K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,284 | $230K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 469 | $220K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,648 | $214K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 700 | $193K |
| 84484 | <1% | 15,953 | $173K | |
| Z7502 | <1% | 4,306 | $160K | |
| 80061 | Lipid panel | <1% | 9,320 | $157K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,916 | $154K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,037 | $145K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 14,971 | $136K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 966 | $135K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 10,876 | $131K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,405 | $130K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,402 | $130K |
| 71250 | <1% | 586 | $129K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,559 | $128K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,319 | $123K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,463 | $122K |
| 81025 | <1% | 14,640 | $112K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 16,394 | $110K |
| 83690 | <1% | 15,009 | $109K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 196 | $107K |
| 76801 | <1% | 1,473 | $103K | |
| 71045 | Radiologic examination, chest; single view | <1% | 8,489 | $99K |
| 99199 | Unlisted special service, procedure or report | <1% | 1,003 | $96K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,148 | $95K |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 74,550 | $94K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 177 | $93K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,896 | $89K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,622 | $87K |
| 81001 | <1% | 24,856 | $86K | |
| 70496 | <1% | 370 | $81K | |
| 93971 | <1% | 627 | $79K | |
| 73610 | <1% | 2,245 | $73K | |
| 73630 | <1% | 2,406 | $70K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,988 | $70K |
| 59025 | Fetal non-stress test | <1% | 1,479 | $64K |
| 73030 | <1% | 2,080 | $64K | |
| 73564 | <1% | 1,820 | $64K | |
| 83880 | <1% | 2,371 | $59K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,291 | $58K |
| 87040 | <1% | 4,068 | $57K | |
| 72131 | <1% | 276 | $56K | |
| 73130 | <1% | 1,687 | $54K | |
| 70498 | <1% | 415 | $51K | |
| 82077 | <1% | 1,884 | $49K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,509 | $49K |
| 90715 | <1% | 1,366 | $48K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,753 | $46K |
| Z9725 | <1% | 1,083 | $46K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 273 | $45K |
| 84702 | <1% | 2,678 | $45K | |
| 87186 | <1% | 3,702 | $45K | |
| 73110 | <1% | 1,405 | $44K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,743 | $42K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,713 | $42K |
| 81003 | <1% | 15,935 | $41K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,995 | $41K |
| 82803 | <1% | 1,401 | $38K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 425 | $37K |
| 83735 | <1% | 5,505 | $37K | |
| 80074 | <1% | 474 | $36K | |
| 87480 | <1% | 1,445 | $36K | |
| 87510 | <1% | 1,445 | $36K | |
| 80143 | <1% | 1,188 | $35K | |
| 73562 | <1% | 1,175 | $34K | |
| 87077 | <1% | 3,322 | $33K | |
| 83605 | <1% | 3,247 | $33K | |
| 86850 | <1% | 3,193 | $33K | |
| 86762 | <1% | 1,423 | $33K | |
| 80179 | <1% | 1,158 | $32K | |
| 74018 | <1% | 1,357 | $31K | |
| 87660 | <1% | 1,419 | $31K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,264 | $29K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,632 | $29K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 756 | $29K |
| 86803 | <1% | 1,237 | $28K | |
| 85610 | <1% | 6,311 | $26K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,632 | $26K |
| 72100 | <1% | 742 | $26K | |
| 85379 | <1% | 2,292 | $25K | |
| 86481 | <1% | 218 | $23K | |
| 87420 | <1% | 1,495 | $23K | |
| 84439 | <1% | 1,996 | $22K | |
| 76830 | Ultrasound, transvaginal | <1% | 234 | $21K |
| 86592 | <1% | 2,814 | $19K | |
| 73221 | <1% | 44 | $19K | |
| J3490 | Unclassified drugs | <1% | 1,167 | $18K |
| 0001A | <1% | 460 | $18K | |
| 87340 | <1% | 1,097 | $18K | |
| 0002A | <1% | 427 | $17K | |
| 73140 | <1% | 767 | $17K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,433 | $16K |
| 87400 | <1% | 3,313 | $16K | |
| 87430 | <1% | 1,359 | $16K | |
| 84481 | <1% | 548 | $16K | |
| 85730 | <1% | 2,536 | $16K | |
| 87081 | <1% | 1,524 | $16K | |
| 86140 | <1% | 2,578 | $15K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,785 | $15K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,133 | $14K |
| 73080 | <1% | 439 | $14K | |
| 0270 | <1% | 1,840 | $13K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 1,205 | $13K |
| 83655 | <1% | 1,976 | $13K | |
| 82947 | <1% | 3,049 | $12K | |
| 84703 | <1% | 1,345 | $12K | |
| 73502 | <1% | 394 | $11K | |
| 70486 | <1% | 41 | $11K | |
| 86901 | <1% | 3,229 | $11K | |
| 86900 | <1% | 3,190 | $11K | |
| 0012A | <1% | 255 | $10K | |
| 0011A | <1% | 250 | $10K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 58 | $9K |
| 76642 | <1% | 119 | $9K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,249 | $9K |
| 85651 | <1% | 1,960 | $9K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,262 | $9K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,010 | $9K |
| 84550 | <1% | 1,383 | $7K | |
| 96367 | <1% | 167 | $7K | |
| 80055 | <1% | 130 | $7K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 750 | $7K |
| J1815 | Injection, insulin, per 5 units | <1% | 545 | $7K |
| 72110 | <1% | 109 | $7K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 211 | $6K |
| 82550 | <1% | 1,108 | $6K | |
| 87088 | <1% | 616 | $6K | |
| 82607 | <1% | 232 | $6K | |
| 82553 | <1% | 662 | $6K | |
| 82043 | <1% | 697 | $6K | |
| 80081 | <1% | 63 | $5K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 147 | $5K |
| 82247 | <1% | 778 | $5K | |
| 72040 | <1% | 144 | $5K | |
| 0250 | <1% | 302 | $5K | |
| 83540 | <1% | 447 | $5K | |
| 84144 | <1% | 125 | $4K | |
| 82746 | <1% | 221 | $4K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 93 | $4K |
| Z7610 | <1% | 436 | $4K | |
| 83550 | <1% | 278 | $4K | |
| 82570 | <1% | 603 | $4K | |
| 0071A | <1% | 98 | $4K | |
| 73590 | <1% | 138 | $4K | |
| 73090 | <1% | 133 | $4K | |
| 82950 | <1% | 610 | $3K | |
| 82728 | <1% | 152 | $3K | |
| 87634 | <1% | 36 | $3K | |
| 96376 | <1% | 113 | $3K | |
| 87070 | <1% | 213 | $3K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 43 | $3K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 485 | $3K |
| 86735 | <1% | 125 | $3K | |
| 82670 | <1% | 56 | $3K | |
| 86765 | <1% | 124 | $3K | |
| 0064A | <1% | 65 | $3K | |
| 0072A | <1% | 65 | $3K | |
| 86003 | <1% | 27 | $2K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 29 | $2K |
| 82248 | <1% | 386 | $2K | |
| 76870 | <1% | 25 | $2K | |
| 80076 | <1% | 231 | $2K | |
| 94644 | <1% | 120 | $2K | |
| 77066 | Tomosynthesis, mammo | <1% | 12 | $2K |
| 76770 | <1% | 24 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 177 | $2K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 267 | $2K |
| 84403 | <1% | 82 | $2K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 168 | $2K |
| L3670 | Shoulder orthosis, acromio/clavicular (canvas and webbing type), prefabricated, off-the-shelf | <1% | 50 | $2K |
| 87147 | <1% | 223 | $2K | |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | <1% | 42 | $2K |
| 86038 | <1% | 70 | $1K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 43 | $1K |
| 86706 | <1% | 70 | $1K | |
| 85018 | <1% | 431 | $1K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 61 | $1K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 24 | $1K |
| 76536 | <1% | 12 | $1K | |
| 85014 | <1% | 334 | $853.27 | |
| 83970 | <1% | 12 | $842.16 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 123 | $810.47 |
| 83001 | <1% | 25 | $784.48 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 34 | $779.22 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 114 | $716.79 |
| 82009 | <1% | 168 | $641.91 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 148 | $625.76 |
| 83002 | <1% | 14 | $435.47 | |
| 84100 | <1% | 78 | $420.46 | |
| 84153 | <1% | 12 | $406.39 | |
| 82270 | <1% | 71 | $399.32 | |
| 84270 | <1% | 12 | $346.96 | |
| 71020 | <1% | 25 | $324.60 | |
| 99283 | Emergency room visit (moderate) | <1% | 16 | $296.98 |
| 86787 | <1% | 17 | $272.71 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 15 | $267.17 |
| 85027 | <1% | 32 | $228.80 | |
| 87045 | <1% | 12 | $208.65 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,972 | $197.40 |
| 82951 | <1% | 12 | $192.50 | |
| 87427 | <1% | 12 | $179.88 | |
| J2471 | Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg | <1% | 39 | $166.62 |
| 87015 | <1% | 12 | $136.32 | |
| 87046 | <1% | 24 | $110.99 | |
| 86430 | <1% | 12 | $100.20 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 21 | $90.67 |
| 87205 | <1% | 15 | $79.14 | |
| 85007 | <1% | 13 | $62.04 | |
| 82952 | <1% | 12 | $58.63 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 14 | $38.18 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 116 | $36.88 |
| 96379 | <1% | 16 | $6.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 25 | $0.45 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTERRA, PAIGE (CFO)
| Provider | Location | Paid |
|---|---|---|
| Sutter Valley Hospitals | Modesto, CA | $76.21M |
| Sutter Coast Hospital | Crescent City, CA | $21.67M |
| Sutter Valley Hospitals | Tracy, CA | $19.42M |
| Sutter Valley Hospitals | Los Banos, CA | $17.26M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.